Litcius/Paper detail

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

Axel Grothey, Josep Tabernero, Julien Taı̈eb, Rona Yaeger, Takayuki Yoshino, Evaristo Maiello, E. Elez Fernandez, A. Ruiz Casado, Paul J. Ross, Thierry André, Takeshi Kato, J.C. Ruffinelli, Janet Graham, Marc Van den Eynde, Ruth Vera, Baptiste Niyibizi Jean, E. Carriere Roussel, C. Cahuzac, Zahida Issiakhem, Jean-Claude Vedovato, Eric Van Cutsem

2020Annals of Oncology37 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCetuximabColorectal cancerOncologyInternal medicineMutantPhases of clinical researchCancer researchCancerClinical trialGeneticsBiologyGeneColorectal Cancer Treatments and StudiesMelanoma and MAPK PathwaysCancer Treatment and Pharmacology
LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer | Litcius